"Sulfonamides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of compounds that contain the structure SO2NH2.
Descriptor ID |
D013449
|
MeSH Number(s) |
D02.065.884 D02.886.590.700
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Sulfonamides".
Below are MeSH descriptors whose meaning is more specific than "Sulfonamides".
This graph shows the total number of publications written about "Sulfonamides" by people in this website by year, and whether "Sulfonamides" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 1 | 0 | 1 |
1996 | 2 | 0 | 2 |
1997 | 1 | 1 | 2 |
2000 | 4 | 2 | 6 |
2001 | 0 | 1 | 1 |
2002 | 4 | 0 | 4 |
2003 | 7 | 3 | 10 |
2004 | 2 | 3 | 5 |
2005 | 2 | 5 | 7 |
2006 | 4 | 6 | 10 |
2007 | 8 | 2 | 10 |
2008 | 8 | 3 | 11 |
2009 | 3 | 4 | 7 |
2010 | 4 | 3 | 7 |
2011 | 6 | 6 | 12 |
2012 | 9 | 2 | 11 |
2013 | 9 | 3 | 12 |
2014 | 9 | 7 | 16 |
2015 | 1 | 5 | 6 |
2016 | 4 | 4 | 8 |
2017 | 4 | 1 | 5 |
2018 | 2 | 2 | 4 |
2019 | 8 | 1 | 9 |
2020 | 4 | 3 | 7 |
2021 | 5 | 6 | 11 |
2022 | 0 | 5 | 5 |
2023 | 1 | 1 | 2 |
2024 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Sulfonamides" by people in Profiles.
-
Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Blood Cancer J. 2024 02 20; 14(1):32.
-
Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. Am J Hematol. 2024 Apr; 99(4):615-624.
-
Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study. Lancet. 2023 08 19; 402(10402):641-654.
-
Peri-operative Reparixin therapy resulted in 50% 5-year insulin independence rate: The University of Chicago experience. Clin Transplant. 2023 05; 37(5):e14981.
-
A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes. Am J Hematol. 2023 02; 98(2):272-281.
-
Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2022 Nov; 6:e2200191.
-
Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia. Clin Cancer Res. 2022 07 01; 28(13):2744-2752.
-
Co-clinical Modeling of the Activity of the BET Inhibitor Mivebresib (ABBV-075) in AML. In Vivo. 2022 Jul-Aug; 36(4):1615-1627.
-
Endothelin-axis antagonism enhances tumor perfusion in pancreatic cancer. Cancer Lett. 2022 09 28; 544:215801.
-
Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study. J Immunother Cancer. 2022 03; 10(3).